Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) Profit After Tax (2023 - 2026)

Kura Oncology has reported Profit After Tax over the past 4 years, most recently at -$73.3 million for Q1 2026.

  • Quarterly Profit After Tax fell 27.69% to -$73.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$294.6 million through Mar 2026, down 61.95% year-over-year, with the annual reading at -$278.7 million for FY2025, 60.17% down from the prior year.
  • Profit After Tax was -$73.3 million for Q1 2026 at Kura Oncology, up from -$81.0 million in the prior quarter.
  • Over five years, Profit After Tax peaked at -$19.2 million in Q4 2024 and troughed at -$81.0 million in Q4 2025.
  • The 4-year median for Profit After Tax is -$50.8 million (2024), against an average of -$52.2 million.
  • Year-over-year, Profit After Tax soared 55.09% in 2024 and then crashed 321.5% in 2025.
  • A 4-year view of Profit After Tax shows it stood at -$42.8 million in 2023, then soared by 55.09% to -$19.2 million in 2024, then tumbled by 321.5% to -$81.0 million in 2025, then increased by 9.46% to -$73.3 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Profit After Tax are -$73.3 million (Q1 2026), -$81.0 million (Q4 2025), and -$74.1 million (Q3 2025).